Skip to main content
    N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $160.21
    -0.29 (-0.18%)

    Market Cap: $303.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novartis AG ADR (NVS) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Novartis AG ADR reported EPS of $2.46, above the $2.25 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(28/41)
    Avg Surprise
    +2.90%
    Streak
    2 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$2.27
    Range$2.05 - $2.43
    12 analysts
    Revenue Consensus
    $15.01B
    Range$13.89B - $16.00B
    13 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$2.27
    Range$2.21 - $2.33
    2 analysts
    EPS Estimate DriftChange to current
    90d ago$2.33-2.6%
    60d ago$2.33-2.6%
    30d ago$2.33-2.6%
    7d ago$2.270.0%
    Current$2.27
    Revenue Consensus
    $14.31B
    Range$14.05B - $14.57B
    2 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 11.8% above the $2.03 reported for the quarter ended Dec 31, 2025.

    NVS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    NVS Earnings Call

    The latest NVS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, NVS beat 27, missed 10 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $15.03B, up 4.7% from $14.36B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.46$2.25$2.22 - $2.26+9.33%Beat+9.3%31 up, 0 downOct 27, 2026$15.03B
    Jun 30, 2026$2.41$2.20N/A+9.55%Beat-0.4%21 up, 0 downJul 21, 2026$14.42B
    Mar 31, 2026$1.65$1.65N/A0.00%In line-27.6%11 up, 0 downApr 28, 2026$13.52B
    Dec 31, 2025$2.03$2.00$1.97 - $2.04+1.50%Beat+2.5%22 up, 0 downFeb 4, 2026$13.33B
    Sep 30, 2025$2.25$2.31$2.30 - $2.32-2.60%Miss+9.2%21 up, 1 downOct 28, 2025$14.36B
    Sep 29, 2025$2.25$2.26N/A-0.44%Miss+9.2%N/AN/AOct 28, 2025$14.36B
    Jun 30, 2025$2.42$2.37$2.34 - $2.41+2.11%Beat+22.8%22 up, 0 downJul 17, 2025$14.84B
    Mar 31, 2025$2.28$2.17$2.15 - $2.19+5.07%Beat+26.7%22 up, 0 downApr 29, 2025$13.62B
    Dec 31, 2024$1.98$1.76$1.74 - $1.84+12.50%Beat+29.4%40 up, 2 downJan 31, 2025$13.56B
    Sep 30, 2024$2.06$1.93$1.88 - $2.01+6.74%Beat+18.4%74 up, 0 downOct 29, 2024$13.17B
    Jun 30, 2024$1.97$1.86$1.84 - $1.94+5.91%Beat+7.7%74 up, 0 downJul 18, 2024$12.87B
    Mar 31, 2024$1.80$1.68$1.54 - $1.77+7.14%Beat+5.3%51 up, 0 downApr 23, 2024$12.12B
    Dec 31, 2023$1.53$1.66$1.58 - $1.80-7.83%Miss+0.7%42 up, 0 downJan 31, 2024$11.78B
    Sep 30, 2023$1.74$1.74N/A0.00%In line+10.1%30 up, 1 downOct 24, 2023$12.09B
    Jun 30, 2023$1.83$1.76N/A+3.98%Beat+17.3%41 up, 1 downJul 18, 2023$11.74B
    Mar 31, 2023$1.71$1.53$1.52 - $1.59+11.76%Beat+17.1%41 up, 0 downApr 25, 2023$11.05B
    Dec 31, 2022$1.52$1.43$1.40 - $1.54+6.29%Beat+8.6%52 up, 0 downFeb 1, 2023$13.09B
    Sep 30, 2022$1.58$1.62N/A-2.47%Miss-7.6%51 up, 0 downOct 25, 2022$10.78B
    Jun 30, 2022$1.56$1.54N/A+1.30%Beat-6.0%N/A0 up, 0 downJul 19, 2022$13.09B
    Mar 31, 2022$1.46$1.51$1.41 - $1.53-3.31%Miss-3.9%52 up, 0 downApr 26, 2022$12.81B
    Dec 31, 2021$1.40$1.41$1.36 - $1.45-0.71%Miss+4.5%61 up, 1 downFeb 2, 2022$13.52B
    Sep 30, 2021$1.71$1.66$1.62 - $1.70+3.01%Beat+12.5%7N/AOct 26, 2021$13.37B
    Jun 30, 2021$1.66$1.49$1.46 - $1.57+11.41%Beat+22.1%5N/AJul 21, 2021$13.29B
    Mar 31, 2021$1.52$1.62$1.52 - $1.69-6.17%Miss-2.6%5N/AApr 27, 2021$12.69B
    Dec 31, 2020$1.34$1.39$1.31 - $1.41-3.60%Miss+1.5%4N/AJan 26, 2021$13.03B
    Sep 30, 2020$1.52$1.45$1.39 - $1.48+4.83%Beat+7.8%5N/AOct 27, 2020$12.54B
    Jun 30, 2020$1.36$1.33$1.25 - $1.43+2.26%Beat+1.5%6N/AJul 21, 2020$11.62B
    Mar 31, 2020$1.56$1.36$1.31 - $1.41+14.71%Beat+28.9%6N/AApr 28, 2020$12.71B
    Dec 31, 2019$1.32$1.31$1.15 - $1.34+0.76%Beat+5.6%6N/AJan 29, 2020$12.72B
    Sep 30, 2019$1.41$1.35$1.30 - $1.41+4.44%Beat+6.8%7N/AOct 22, 2019$12.48B
    Jun 30, 2019$1.34$1.23$1.19 - $1.27+8.94%Beat+3.9%7N/AJul 18, 2019$12.02B
    Mar 31, 2019$1.21$1.21$1.15 - $1.250.00%In line-5.5%5N/AApr 24, 2019$11.46B
    Dec 31, 2018$1.25$1.30$1.20 - $1.41-3.85%Miss+3.3%7N/AJan 30, 2019$13.66B
    Sep 30, 2018$1.32$1.34$1.27 - $1.36-1.49%Miss+2.3%6N/AOct 18, 2018$11.39B
    Jun 30, 2018$1.29$1.28$1.25 - $1.30+0.78%Beat+5.7%9N/AJul 18, 2018$11.65B
    Mar 31, 2018$1.28$1.27$1.26 - $1.32+0.79%Beat+13.3%5N/AApr 19, 2018$11.16B
    Dec 31, 2017$1.21$1.17$1.13 - $1.29+3.42%Beat+8.0%9N/AJan 24, 2018$13.16B
    Sep 30, 2017$1.29$1.24$1.17 - $1.28+4.03%Beat+4.9%8N/AOct 24, 2017$12.69B
    Jun 30, 2017$1.22$1.17$1.15 - $1.22+4.27%Beat-0.8%9N/AJul 18, 2017$12.49B
    Mar 31, 2017$1.13$1.10N/A+2.73%Beat-3.4%N/AN/AApr 25, 2017$11.79B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $8.98, up 15.0% from the year before. It was $4.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$8.98+15.0%
    Dec 31, 2024$7.81+14.7%
    Dec 31, 2023$6.81+11.3%
    Dec 31, 2022$6.12-2.7%
    Dec 31, 2021$6.29+8.8%
    Dec 31, 2020$5.78+9.5%
    Dec 31, 2019$5.28+2.7%
    Dec 31, 2018$5.14+6.0%
    Dec 31, 2017$4.85+2.1%
    Dec 31, 2016$4.75N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 22 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202611,12322
    2026Q2Jun 30, 20268,44620
    2025Q4Dec 31, 20258,19017
    2025Q3Sep 30, 20258,00516
    2025Q2Jun 30, 20256,19714
    2025Q1Mar 31, 20256,82116
    2024Q4Dec 31, 20247,59116
    2024Q3Sep 30, 202410,05818

    2026Q3 Earnings Call

    Opening remarks

    Vasant Narasimhan CEO Thank you, Sharon. Hi, everyone, and welcome to our Q3 earnings call. Let me briefly read the safe harbor statement before we begin. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by these statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K, which were filed with and furnished to the U.S. Securities and Exchange Commission, respectively. And with that, I will hand over to Robert.

    Robert Kowalski Executive Thank you, Isabella, and thanks, everybody, for joining today's call. If we could move to slide 4. So, in the quarter—hold on one second. We are just getting our slides moving here. In the quarter, Novartis delivered sales growth and core margin expansion. That supported an upgrade to our full-year 2026 bottom-line guidance. You can see sales were up 4% in constant currency. Core operating income was up 10%. Mukul will go into the numbers in more detail, but we also had good margin performance in the quarter. There were a number of important pipeline milestones, notably, of course, as you all know, the remibrutinib data. Repsido also received FDA approval; Pluvicto received important approvals in the U.S. and China for HSPC; pelabresib was also filed in Europe; and Delzota received FDA priority review for DMD44. Overall, this allowed us to increase our guidance, and we will go through that in a bit more detail on the call. So, moving to the next slide. Priority brands continue to perform well. In the quarter, they were up 29%. There was very strong performance across Kisqali, Kesimpta, Scemblix, and Leqvio. A solid quarter from Cosentyx. Pluvicto: we are still in the midst of launching in HSPC, so we have not seen that pick up yet, and we will talk more about that in a bit. Rhapsido also had a very strong performance in the quarter. Moving to slide 6. Kisqali grew 37%, and it continued to take market share. You can see that our EBC shares in both the U.S. and Germany are very stable and at a very healthy level. Now, turning to the U.S. first: 38% growth in the quarter, $3 billion year to date. We are the leader in EBC, and our NBRx share was up 3 points versus the prior quarter. Fifty-three percent of the patients now on Kisqali are from the exclusive population. In metastatic disease, we are continuing to grow our NBRx share in first line, which is now at 55%.

    Frequently Asked Questions About NVS

    Did NVS beat earnings estimates last quarter?

    Yes. Novartis AG ADR reported EPS of $2.46 for the quarter ended Sep 30, 2026, above the $2.25 estimate, a 9.33% surprise.

    What EPS do analysts expect from NVS next quarter?

    The consensus EPS estimate for Novartis AG ADR for the quarter ending Dec 31, 2026 is $2.27 from 12 analysts, with estimates from $2.05 to $2.43.

    How often does NVS beat earnings estimates?

    Novartis AG ADR beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.06%.